Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2017 (2017), Article ID 3187594, 11 pages
https://doi.org/10.1155/2017/3187594
Review Article

Sirtuins Expression and Their Role in Retinal Diseases

1Department of Ophthalmology, University of Florida College of Medicine, 580 W. 8th Street, Tower-2, Jacksonville, FL 32209, USA
2The Vanderbilt Eye Institute, Vanderbilt University Medical Center, Nashville, TN, USA
3Glaucoma Research Chair, Department of Ophthalmology, College of Medicine, King Saud University, Riyadh 11424, Saudi Arabia

Correspondence should be addressed to Sankarathi Balaiya; moc.liamg@lfu.gbs and Kakarla V. Chalam; moc.loa@malahcvk

Received 26 September 2016; Accepted 13 December 2016; Published 19 January 2017

Academic Editor: Yuhei Nishimura

Copyright © 2017 Sankarathi Balaiya et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. R. MacAskill and T. J. Anderson, “Eye movements in neurodegenerative diseases,” Current Opinion in Neurology, vol. 29, no. 1, pp. 61–68, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. V. V. Ermilov and A. A. Nesterova, “β-amyloidopathy in the pathogenesis of age-related macular degeneration in correlation with neurodegenerative diseases,” Advances in Experimental Medicine and Biology, vol. 854, pp. 119–125, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Jones-Odeh and C. J. Hammond, “How strong is the relationship between glaucoma, the retinal nerve fibre layer, and neurodegenerative diseases such as Alzheimer's disease and multiple sclerosis,” Eye, vol. 29, no. 10, pp. 1270–1284, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. A. A. Sauve, C. Wolberger, V. L. Schramm, and J. D. Boeke, “The biochemistry of sirtuins,” Annual Review of Biochemistry, vol. 75, pp. 435–465, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S.-I. Imai, C. M. Armstrong, M. Kaeberlein, and L. Guarente, “Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase,” Nature, vol. 403, no. 6771, pp. 795–800, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Brochier, G. Dennis, M. A. Rivieccio et al., “Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons,” Journal of Neuroscience, vol. 33, no. 20, pp. 8621–8632, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kaeberlein, M. McVey, and L. Guarente, “The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms,” Genes & Development, vol. 13, no. 19, pp. 2570–2580, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Wojcik, K. Mac-Marcjanek, and L. A. Wozniak, “Physiological and pathophysiological functions of SIRT1,” Mini-Reviews in Medicinal Chemistry, vol. 9, no. 3, pp. 386–394, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Han, B. P. Hubbard, J. Lee et al., “Analysis of 41 cancer cell lines reveals excessive allelic loss and novel mutations in the SIRT1 gene,” Cell Cycle, vol. 12, no. 2, pp. 263–270, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. Y. Ozawa, S. Kubota, T. Narimatsu et al., “Retinal aging and sirtuins,” Ophthalmic Research, vol. 44, no. 3, pp. 199–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Mimura, Y. Kaji, H. Noma, H. Funatsu, and S. Okamoto, “The role of SIRT1 in ocular aging,” Experimental Eye Research, vol. 116, pp. 17–26, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. B. D. Sanders, B. Jackson, and R. Marmorstein, “Structural basis for sirtuin function: what we know and what we don't,” Biochimica et Biophysica Acta (BBA)—Proteins and Proteomics, vol. 1804, no. 8, pp. 1604–1616, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. Y. Cen, D. Y. Youn, and A. A. Sauve, “Advances in characterization of human sirtuin isoforms: chemistries, targets and therapeutic applications,” Current Medicinal Chemistry, vol. 18, no. 13, pp. 1919–1935, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. M. S. Finnin, J. R. Donigian, and N. P. Pavletich, “Structure of the histone deacetylase SIRT2,” Nature Structural Biology, vol. 8, no. 7, pp. 621–625, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Chalkiadaki and L. Guarente, “The multifaceted functions of sirtuins in cancer,” Nature Reviews Cancer, vol. 15, no. 10, pp. 608–624, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Xu, F. Li, L. Lv et al., “Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase,” Cancer Research, vol. 74, no. 13, pp. 3630–3642, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Yi and J. Luo, “SIRT1 and p53, effect on cancer, senescence and beyond,” Biochimica et Biophysica Acta—Proteins and Proteomics, vol. 1804, no. 8, pp. 1684–1689, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Z. Herskovits and L. Guarente, “Sirtuin deacetylases in neurodegenerative diseases of aging,” Cell Research, vol. 23, no. 6, pp. 746–758, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Zhang, S.-H. Park, B. G. Pantazides et al., “SIRT2 directs the replication stress response through CDK9 deacetylation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 33, pp. 13546–13551, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. N. Preyat, M. Rossi, J. Kers et al., “Intracellular nicotinamide adenine dinucleotide promotes TNF-induced necroptosis in a sirtuin-dependent manner,” Cell Death and Differentiation, vol. 23, no. 1, pp. 29–40, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Newton, J. M. Hildebrand, Z. Shen et al., “Is SIRT2 required for necroptosis?” Nature, vol. 506, no. 7489, pp. E4–E6, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Li, M. Banck, S. Mujtaba, M.-M. Zhou, M. M. Sugrue, and M. J. Walsh, “p53-Induced growth arrest is regulated by the Mitochondrial SirT3 deacetylase,” PLoS ONE, vol. 5, no. 5, Article ID e10486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Kamarajan, T. Y. Alhazzazi, T. Danciu, N. J. D'Silva, E. Verdin, and Y. L. Kapila, “Receptor-interacting protein (RIP) and Sirtuin-3 (SIRT3) are on opposite sides of anoikis and tumorigenesis,” Cancer, vol. 118, no. 23, pp. 5800–5810, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. N. R. Sundaresan, S. A. Samant, V. B. Pillai, S. B. Rajamohan, and M. P. Gupta, “SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70,” Molecular and Cellular Biology, vol. 28, no. 20, pp. 6384–6401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. E. L. Bell, B. M. Emerling, S. J. H. Ricoult, and L. Guarente, “SirT3 suppresses hypoxia inducible factor 1α and tumor growth by inhibiting mitochondrial ROS production,” Oncogene, vol. 30, no. 26, pp. 2986–2996, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. R. A. Mathias, T. M. Greco, A. Oberstein et al., “Sirtuin 4 is a lipoamidase regulating pyruvate dehydrogenase complex activity,” Cell, vol. 159, no. 7, pp. 1615–1625, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Nasrin, X. Wu, E. Fortier et al., “SIRT4 regulates fatty acid oxidation and mitochondrial gene expression in liver and muscle cells,” The Journal of Biological Chemistry, vol. 285, no. 42, pp. 31995–32002, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. J. Rardin, W. He, Y. Nishida et al., “SIRT5 regulates the mitochondrial lysine succinylome and metabolic networks,” Cell Metabolism, vol. 18, no. 6, pp. 920–933, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. Y. Nishida, M. J. Rardin, C. Carrico et al., “SIRT5 regulates both cytosolic and mitochondrial protein malonylation with glycolysis as a major target,” Molecular Cell, vol. 59, no. 2, pp. 321–332, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. J. Du, Y. Zhou, X. Su et al., “Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase,” Science, vol. 334, no. 6057, pp. 806–809, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Mostoslavsky, K. F. Chua, D. B. Lombard et al., “Genomic instability and aging-like phenotype in the absence of mammalian SIRT6,” Cell, vol. 124, no. 2, pp. 315–329, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. Y. Kanfi, S. Naiman, G. Amir et al., “The sirtuin SIRT6 regulates lifespan in male mice,” Nature, vol. 483, no. 7388, pp. 218–221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. D. Ryu, Y. S. Jo, G. Lo Sasso et al., “A SIRT7-dependent acetylation switch of GABPβ1 controls mitochondrial function,” Cell Metabolism, vol. 20, no. 5, pp. 856–869, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. J. Yang, X. Kong, M. E. S. Martins-Santos et al., “Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4α,” The Journal of Biological Chemistry, vol. 284, no. 40, pp. 27042–27053, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. E. Sidorova-Darmos, R. G. Wither, N. Shulyakova et al., “Differential expression of sirtuin family members in the developing, adult, and aged rat brain,” Frontiers in Aging Neuroscience, vol. 6, article 333, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Ames III and Y.-Y. Li, “Energy requirements of glutamatergic pathways in rabbit retina,” The Journal of Neuroscience, vol. 12, no. 11, pp. 4234–4242, 1992. View at Google Scholar · View at Scopus
  37. J. E. Niven and S. B. Laughlin, “Energy limitation as a selective pressure on the evolution of sensory systems,” The Journal of Experimental Biology, vol. 211, no. 11, pp. 1792–1804, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. N. Ban, Y. Ozawa, T. Inaba et al., “Light-dark condition regulates sirtuin mRNA levels in the retina,” Experimental Gerontology, vol. 48, no. 11, pp. 1212–1217, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Jaliffa, I. Ameqrane, A. Dansault et al., “Sirt1 involvement in rd10 mouse retinal degeneration,” Investigative Ophthalmology & Visual Science, vol. 50, no. 8, pp. 3562–3572, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. M. W. McBurney, X. Yang, K. Jardine et al., “The mammalian SIR2α protein has a role in embryogenesis and gametogenesis,” Molecular and Cellular Biology, vol. 23, no. 1, pp. 38–54, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. H.-L. Cheng, R. Mostoslavsky, S. Saito et al., “Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 19, pp. 10794–10799, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. T. Zheng and Y. Lu, “Changes in SIRT1 expression and its downstream pathways in age-related cataract in humans,” Current Eye Research, vol. 36, no. 5, pp. 449–455, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. T.-J. Lin, C.-H. Peng, S.-H. Chiou et al., “Severity of lens opacity, age, and correlation of the level of silent information regulator T1 expression in age-related cataract,” Journal of Cataract and Refractive Surgery, vol. 37, no. 7, pp. 1270–1274, 2011. View at Publisher · View at Google Scholar · View at Scopus
  44. T. S. Anekonda and G. Adamus, “Resveratrol prevents antibody-induced apoptotic death of retinal cells through upregulation of Sirt1 and Ku70,” BMC Research Notes, vol. 1, article 122, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Kurihara, Y. Kubota, Y. Ozawa et al., “Von Hippel-Lindau protein regulates transition from the fetal to the adult circulatory system in retina,” Development, vol. 137, no. 9, pp. 1563–1571, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. K. S. Shindler, E. Ventura, T. S. Rex, P. Elliott, and A. Rostami, “SIRT1 activation confers neuroprotection in experimental optic neuritis,” Investigative Ophthalmology & Visual Science, vol. 48, no. 8, pp. 3602–3609, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Kubota, T. Kurihara, H. Mochimar et al., “Prevention of ocular inflammation in endotoxin-induced uveitis with resveratrol by inhibiting oxidative damage and nuclear factor-κB activation,” Investigative Ophthalmology & Visual Science, vol. 50, no. 7, pp. 3512–3519, 2009. View at Publisher · View at Google Scholar · View at Scopus
  48. M. E. Orellana, C. Quezada, S. C. Maloney, E. Antecka, M. Balazsi, and M. N. Burnier, “Expression of SIRT2 and SIRT6 in retinoblastoma,” Ophthalmic Research, vol. 53, no. 2, pp. 100–108, 2015. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Ban, S. Miyake, N. Takahashi, K. Tsubota, and Y. Ozawa, “Sirt3 expression in ocular tissues of mouse,” Investigative Ophthalmology & Visual Science, vol. 53, no. 14, p. 776, 2012. View at Google Scholar
  50. N. Ban, T. Inaba, S. Milyake, K. Tsubota, and Y. Ozawa, “Analysis of SIRT3 function in the mouse retina,” in Proceedings of the ARVO Annual Meeting, vol. 55, p. 6172, 2014.
  51. N. Vilà, P. Zoroquiain, S. C. Maloney, A. B. T. Dias, E. Antecka, and M. N. Burnier, “Sirtuins are differentially expressed in distinct retinal layers,” in Proceedings of the ARVO Annual Meeting, vol. 55, p. 1853, 2014.
  52. D. M. Silberman, K. Ross, P. H. Sande et al., “SIRT6 is required for normal retinal function,” PLoS ONE, vol. 9, no. 6, Article ID e98831, 2014. View at Publisher · View at Google Scholar · View at Scopus
  53. M. B. Wax, C. B. Camras, R. G. Fiscella, C. Girkin, K. Singh, and R. N. Weinreb, “Emerging perspectives in glaucoma: optimizing 24-hour control of intraocular pressure,” American Journal of Ophthalmology, vol. 133, no. 6, pp. S1–S10, 2002. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Balaiya, L. R. Ferguson, and K. V. Chalam, “Evaluation of sirtuin role in neuroprotection of retinal ganglion cells in hypoxia,” Investigative Ophthalmology & Visual Science, vol. 53, no. 7, pp. 4315–4322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. Y.-N. Chen, H. Yamada, W. Mao, S. Matsuyama, M. Aihara, and M. Araie, “Hypoxia-induced retinal ganglion cell death and the neuroprotective effects of beta-adrenergic antagonists,” Brain Research, vol. 1148, no. 1, pp. 28–37, 2007. View at Publisher · View at Google Scholar · View at Scopus
  56. E. M. Dioum, R. Chen, M. S. Alexander et al., “Regulation of hypoxia-inducible factor 2α signaling by the stress-responsive deacetylase Sirtuin 1,” Science, vol. 324, no. 5932, pp. 1289–1293, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. J.-H. Lim, Y.-M. Lee, Y.-S. Chun, J. Chen, J.-E. Kim, and J.-W. Park, “Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha,” Molecular Cell, vol. 38, no. 6, pp. 864–878, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Levkovitch-Verbin, H. A. Quigley, K. R. G. Martin et al., “The transcription factor c-jun is activated in retinal ganglion cells in experimental rat glaucoma,” Experimental Eye Research, vol. 80, no. 5, pp. 663–670, 2005. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Bien, C. I. Seidenbecher, T. M. Böckers, B. A. Sabel, and M. R. Kreutz, “Apoptotic versus necrotic characteristics of retinal ganglion cell death after partial optic nerve injury,” Journal of Neurotrauma, vol. 16, no. 2, pp. 153–163, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. P. W. Mesner, C. L. Epting, J. L. Hegarty, and S. H. Green, “A timetable of events during programmed cell death induced by trophic factor withdrawal from neuronal PC12 cells,” The Journal of Neuroscience, vol. 15, no. 11, pp. 7357–7366, 1995. View at Google Scholar · View at Scopus
  61. L. Zuo, R. S. Khan, V. Lee, K. Dine, W. Wu, and K. S. Shindler, “SIRT1 promotes RGC survival and delays loss of function following optic nerve crush,” Investigative Ophthalmology & Visual Science, vol. 54, no. 7, pp. 5097–5102, 2013. View at Publisher · View at Google Scholar · View at Scopus
  62. Y. Geng, J. Wang, J. Liang, C. Xu, and Y. Zhi, “Expression of Sirt1 and Sirt2 in injured optic retina of calorie restricted rats,” Eye Science, vol. 26, no. 4, pp. 221–224, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. J. D. Lindsey, K. X. Duong-Polk, and R. N. Weinreb, “Altered expression of Sirt-1, Sirt2 and Sirt5 linked with RGC protective effect of resveratrol following optic nerve injury,” in Proceedings of the ARVO Annual Meeting, vol. 57, p. 2557, Seattle, Wash, USA, May 2016.
  64. X. Yang, J. Cai, D. W. Powell, H. Paladugu, M. H. Kuehn, and G. Tezel, “Up-regulation of sirtuins in the glaucomatous human retina,” in Proceedings of the ARVO Annual Meeting, vol. 55, p. 2398, Orlando, Fla, USA, May 2014.
  65. S. Balaiya, R. K. Murthy, and K. V. Chalam, “Resveratrol inhibits proliferation of hypoxic choroidal vascular endothelial cells,” Molecular Vision, vol. 19, pp. 2385–2392, 2013. View at Google Scholar · View at Scopus
  66. A. E. Fletcher, “Free radicals, antioxidants and eye diseases: evidence from epidemiological studies on cataract and age-related macular degeneration,” Ophthalmic Research, vol. 44, no. 3, pp. 191–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  67. B. S. Winkler, M. E. Boulton, J. D. Gottsch, and P. Sternberg, “Oxidative damage and age-related macular degeneration,” Molecular Vision, vol. 5, p. 32, 1999. View at Google Scholar · View at Scopus
  68. S. Balaiya, V. Khetpal, and K. V. Chalam, “Hypoxia initiates sirtuin1-mediated vascular endothelial growth factor activation in choroidal endothelial cells through hypoxia inducible factor-2α,” Molecular Vision, vol. 18, pp. 114–120, 2012. View at Google Scholar · View at Scopus
  69. S. Richer, W. Stiles, L. Ulanski, D. Carroll, and C. Podella, “Observation of human retinal remodeling in octogenarians with a resveratrol based nutritional supplement,” Nutrients, vol. 5, no. 6, pp. 1989–2005, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. S. Richer, S. Patel, S. Sockanathan, L. J. Ulanski II, L. Miller, and C. Podella, “Resveratrol based oral nutritional supplement produces long-term beneficial effects on structure and visual function in human patients,” Nutrients, vol. 6, no. 10, pp. 4404–4420, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Kubota, T. Kurihara, M. Ebinuma et al., “Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation,” The American Journal of Pathology, vol. 177, no. 4, pp. 1725–1731, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. L. Cao, C. Liu, F. Wang, and H. Wang, “SIRT1 negatively regulates amyloid-beta-induced inflammation via the NF-κB pathway,” Brazilian Journal of Medical and Biological Research, vol. 46, no. 8, pp. 659–669, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. T. A. Quinn, M. Dutt, and K. S. Shindler, “Optic neuritis and retinal ganglion cell loss in a chronic murine model of multiple sclerosis,” Frontiers in Neurology, vol. 2, article no. 50, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. K. S. Shindler, Y. Guan, E. Ventura, J. Bennett, and A. Rostami, “Retinal ganglion cell loss induced by acute optic neuritis in a relapsing model of multiple sclerosis,” Multiple Sclerosis, vol. 12, no. 5, pp. 526–532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. A. P. D. Henderson, D. R. Altmann, A. S. Trip et al., “A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials,” Brain, vol. 133, no. 9, pp. 2592–2602, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. K. S. Shindler, E. Ventura, M. Dutt, P. Elliott, D. C. Fitzgerald, and A. Rostami, “Oral resveratrol reduces neuronal damage in a model of multiple sclerosis,” Journal of Neuro-Ophthalmology, vol. 30, no. 4, pp. 328–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Chen, X. Jiang, W. Zhao, and Z. Zhang, “Dual role of resveratrol in modulation of genotoxicity induced by sodium arsenite via oxidative stress and apoptosis,” Food and Chemical Toxicology, vol. 59, pp. 8–17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. V. A. Rafalski, P. P. Ho, J. O. Brett et al., “Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain,” Nature Cell Biology, vol. 15, no. 6, pp. 614–624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Chen, Y. Zhou, S. Mueller-Steiner et al., “SIRT1 protects against microglia-dependent amyloid-β toxicity through inhibiting NF-κB signaling,” The Journal of Biological Chemistry, vol. 280, no. 48, pp. 40364–40374, 2005. View at Publisher · View at Google Scholar · View at Scopus
  80. K. C. Morris, H. W. Lin, J. W. Thompson, and M. A. Perez-Pinzon, “Pathways for ischemic cytoprotection: role of sirtuins in caloric restriction, resveratrol, and ischemic preconditioning,” Journal of Cerebral Blood Flow and Metabolism, vol. 31, no. 4, pp. 1003–1019, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. A. P. Raval, K. R. Dave, and M. A. Pérez-Pinzón, “Resveratrol mimics ischemic preconditioning in the brain,” Journal of Cerebral Blood Flow and Metabolism, vol. 26, no. 9, pp. 1141–1147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. F. Longpré, P. Garneau, Y. christen, and C. Ramassamy, “Protection by EGb 761 against β-amyloid-induced neurotoxicity: involvement of NF-κB, SIRT1, and MAPKs pathways and inhibition of amyloid fibril formation,” Free Radical Biology & Medicine, vol. 41, no. 12, pp. 1781–1794, 2006. View at Publisher · View at Google Scholar · View at Scopus
  83. H. Wang, Y. Xu, J. Yan et al., “Acteoside protects human neuroblastoma SH-SY5Y cells against β-amyloid-induced cell injury,” Brain Research, vol. 1283, pp. 139–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. F. Jin, Q. Wu, Y.-F. Lu, Q.-H. Gong, and J.-S. Shi, “Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats,” European Journal of Pharmacology, vol. 600, no. 1–3, pp. 78–82, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. S. S. Karuppagounder, J. T. Pinto, H. Xu, H.-L. Chen, M. F. Beal, and G. E. Gibson, “Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease,” Neurochemistry International, vol. 54, no. 2, pp. 111–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  86. Resveratrol for Alzheimer's Disease, 2012, http://clinicaltrials.gov/ct2/show/NCT01504854.
  87. Randomized Trial of a Nutritional Supplement in Alzheimer's Disease, http://www.clinicaltrials.gov/ct2/show/NCT00678431.
  88. J. Shih, L. Liu, A. Mason, H. Higashimori, and G. Donmez, “Loss of SIRT4 decreases GLT-1-dependent glutamate uptake and increases sensitivity to kainic acid,” Journal of Neurochemistry, vol. 131, no. 5, pp. 573–581, 2014. View at Publisher · View at Google Scholar · View at Scopus
  89. R. Raynes, B. D. Leckey Jr., K. Nguyen, and S. D. Westerheide, “Heat shock and caloric restriction have a synergistic effect on the heat shock response in a sir2.1-dependent manner in Caenorhabditis elegans,” The Journal of Biological Chemistry, vol. 287, no. 34, pp. 29045–29053, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. L. Liu, A. Arun, L. Ellis, C. Peritore, and G. Donmez, “Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating bim protein,” Journal of Biological Chemistry, vol. 287, no. 39, pp. 32307–32311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Liu, C. Peritore, J. Ginsberg, J. Shih, S. Arun, and G. Donmez, “Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease,” Behavioural Brain Research, vol. 281, pp. 215–221, 2015. View at Publisher · View at Google Scholar · View at Scopus
  92. A. R. La Spada, “Finding a sirtuin truth in Huntington's disease,” Nature Medicine, vol. 18, no. 1, pp. 24–26, 2012. View at Publisher · View at Google Scholar · View at Scopus
  93. P. Kumar, S. S. V. Padi, P. S. Naidu, and A. Kumar, “Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms,” Behavioural Pharmacology, vol. 17, no. 5-6, pp. 485–492, 2006. View at Publisher · View at Google Scholar · View at Scopus
  94. D. J. Ho, N. Y. Calingasan, E. Wille, M. Dumont, and M. F. Beal, “Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease,” Experimental Neurology, vol. 225, no. 1, pp. 74–84, 2010. View at Publisher · View at Google Scholar · View at Scopus
  95. R. Luthi-Carter, D. M. Taylor, J. Pallos et al., “SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 17, pp. 7927–7932, 2010. View at Publisher · View at Google Scholar · View at Scopus
  96. J. Fu, J. Jin, R. H. Cichewicz et al., “Trans-(-)-ε-viniferin increases mitochondrial sirtuin 3 (SIRT3), activates AMP-activated Protein Kinase (AMPK), and protects cells in models of huntington disease,” Journal of Biological Chemistry, vol. 287, no. 29, pp. 24460–24472, 2012. View at Publisher · View at Google Scholar · View at Scopus
  97. J. T. Rodgers, C. Lerin, W. Haas, S. P. Gygi, B. M. Spiegelman, and P. Puigserver, “Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1,” Nature, vol. 434, no. 7029, pp. 113–118, 2005. View at Publisher · View at Google Scholar · View at Scopus
  98. A. Raghavan and Z. A. Shah, “Sirtuins in neurodegenerative diseases: a biological-chemical perspective,” Neurodegenerative Diseases, vol. 9, no. 1, pp. 1–10, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. W. Jiang, S. Wang, M. Xiao et al., “Acetylation regulates gluconeogenesis by promoting pepck1 degradation via recruiting the ubr5 ubiquitin ligase,” Molecular Cell, vol. 43, no. 1, pp. 33–44, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Kim, H. Chung, C. Yoon et al., “Increase of INS-1 cell apoptosis under glucose fluctuation and the involvement of FOXO-SIRT pathway,” Diabetes Research and Clinical Practice, vol. 98, no. 1, pp. 132–139, 2012. View at Publisher · View at Google Scholar · View at Scopus
  101. F. Wang, M. Nguyen, F. X.-F. Qin, and Q. Tong, “SIRT2 deacetylates FOXO3a in response to oxidative stress and caloric restriction,” Aging Cell, vol. 6, no. 4, pp. 505–514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  102. T. Chen, J. Li, J. Liu et al., “Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via the TGF-β/Smad3 pathway,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 308, no. 5, pp. H424–H434, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. W. C. Hallows, S. Lee, and J. M. Denu, “Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 27, pp. 10230–10235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  104. B.-H. Ahn, H.-S. Kim, S. Song et al., “A role for the mitochondrial deacetylase Sirt3 in regulating energy homeostasis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14447–14452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. M. C. Haigis, R. Mostoslavsky, K. M. Haigis et al., “SIRT4 inhibits glutamate dehydrogenase and opposes the effects of calorie restriction in pancreatic β cells,” Cell, vol. 126, no. 5, pp. 941–954, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. T. Nakagawa, D. J. Lomb, M. C. Haigis, and L. Guarente, “Sirt5 deacetylates carbamoyl phosphate synthetase 1 and regulates the urea cycle,” Cell, vol. 137, no. 3, pp. 560–570, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. L. Zhong, A. D'Urso, D. Toiber et al., “The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1α,” Cell, vol. 140, no. 2, pp. 280–293, 2010. View at Publisher · View at Google Scholar · View at Scopus
  108. T. L. A. Kawahara, N. A. Rapicavoli, A. R. Wu, K. Qu, S. R. Quake, and H. Y. Chang, “Dynamic chromatin localization of sirt6 shapes stress- and aging-related transcriptional networks,” PLoS Genetics, vol. 7, no. 6, Article ID e1002153, 2011. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Winnik, J. Auwerx, D. A. Sinclair, and C. M. Matter, “Protective effects of sirtuins in cardiovascular diseases: from bench to bedside,” European Heart Journal, vol. 36, no. 48, pp. 3404–3412, 2015. View at Publisher · View at Google Scholar
  110. T. L. A. Kawahara, E. Michishita, A. S. Adler et al., “SIRT6 links histone H3 lysine 9 deacetylation to control of NF-κB dependent gene expression and organismal lifespan,” Cell, vol. 136, no. 1, pp. 62–74, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. R. R. Alcendor, L. A. Kirshenbaum, S.-I. Imai, S. F. Vatner, and J. Sadoshima, “Silent information regulator 2α, a longevity factor and class III histone deacetylase, is an essential endogenous apoptosis inhibitor in cardiac myocytes,” Circulation Research, vol. 95, no. 10, pp. 971–980, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. Q.-J. Zhang, Z. Wang, H.-Z. Chen et al., “Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice,” Cardiovascular Research, vol. 80, no. 2, pp. 191–199, 2008. View at Publisher · View at Google Scholar · View at Scopus
  113. S. Winnik, S. Stein, and C. M. Matter, “SIRT1—an anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis,” Current Vascular Pharmacology, vol. 10, no. 6, pp. 693–696, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. A. Breitenstein, S. Stein, E. W. Holy et al., “Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells,” Cardiovascular Research, vol. 89, no. 2, pp. 464–472, 2011. View at Publisher · View at Google Scholar · View at Scopus
  115. S. S. Barbieri, P. Amadio, S. Gianellini et al., “Cyclooxygenase-2-derived prostacyclin regulates arterial thrombus formation by suppressing tissue factor in a sirtuin-1-dependent-manner,” Circulation, vol. 126, no. 11, pp. 1373–1384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. S. J. Thandapilly, P. Wojciechowski, J. Behbahani et al., “Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure,” American Journal of Hypertension, vol. 23, no. 2, pp. 192–196, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. H. Ozawa, S. Miyagawa, S. Fukushima et al., “Sirtuin1 regulates the stem cell therapeutic effects on regenerative capability for treating severe heart failure in a juvenile animal model,” The Annals of Thoracic Surgery, vol. 102, no. 3, pp. 803–812, 2016. View at Publisher · View at Google Scholar
  118. N. R. Sundaresan, M. Gupta, G. Kim, S. B. Rajamohan, A. Isbatan, and M. P. Gupta, “Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice,” The Journal of Clinical Investigation, vol. 119, no. 9, pp. 2758–2771, 2009. View at Publisher · View at Google Scholar · View at Scopus
  119. R. Paulin, P. Dromparis, G. Sutendra et al., “Sirtuin 3 deficiency is associated with inhibited mitochondrial function and pulmonary arterial hypertension in rodents and humans,” Cell Metabolism, vol. 20, no. 5, pp. 827–839, 2014. View at Publisher · View at Google Scholar · View at Scopus
  120. N. R. Sundaresan, P. Vasudevan, L. Zhong et al., “The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun,” Nature Medicine, vol. 18, no. 11, pp. 1643–1650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. S. Matsushima and J. Sadoshima, “The role of sirtuins in cardiac disease,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 309, no. 9, pp. H1375–H1389, 2015. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Araki, Y. Izumiya, T. Rokutanda et al., “Sirt7 contributes to myocardial tissue repair by maintaining transforming growth factor-β signaling pathway,” Circulation, vol. 132, no. 12, pp. 1081–1093, 2015. View at Publisher · View at Google Scholar · View at Scopus
  123. J. Hu, H. Jing, and H. Lin, “Sirtuin inhibitors as anticancer agents,” Future Medicinal Chemistry, vol. 6, no. 8, pp. 945–966, 2014. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Roth and W. Y. Chen, “Sorting out functions of sirtuins in cancer,” Oncogene, vol. 33, no. 13, pp. 1609–1620, 2014. View at Publisher · View at Google Scholar · View at Scopus
  125. B. J. Morris, “Seven sirtuins for seven deadly diseases of aging,” Free Radical Biology and Medicine, vol. 56, pp. 133–171, 2013. View at Publisher · View at Google Scholar · View at Scopus
  126. H.-S. Kim, A. Vassilopoulos, R.-H. Wang et al., “SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity,” Cancer Cell, vol. 20, no. 4, pp. 487–499, 2011. View at Publisher · View at Google Scholar · View at Scopus
  127. S. M. Jeong and M. C. Haigis, “Sirtuins in cancer: a balancing act between genome stability and metabolism,” Molecules and Cells, vol. 38, no. 9, pp. 750–758, 2015. View at Publisher · View at Google Scholar · View at Scopus
  128. P. Y. Liu, N. Xu, A. Malyukova et al., “The histone deacetylase SIRT2 stabilizes Myc oncoproteins,” Cell Death and Differentiation, vol. 20, no. 3, pp. 503–514, 2013. View at Publisher · View at Google Scholar · View at Scopus
  129. A. R. McCarthy, M. C. C. Sachweh, M. Higgins et al., “Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 (CDKN1A) expression in a p53-independent manner,” Molecular Cancer Therapeutics, vol. 12, no. 4, pp. 352–360, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. D. Zhao, S.-W. Zou, Y. Liu et al., “Lysine-5 acetylation negatively regulates lactate dehydrogenase A and is decreased in pancreatic cancer,” Cancer Cell, vol. 23, no. 4, pp. 464–476, 2013. View at Publisher · View at Google Scholar · View at Scopus
  131. Y. Cui, L. Qin, J. Wu et al., “SIRT3 enhances glycolysis and proliferation in SIRT3-expressing gastric cancer cells,” PLoS ONE, vol. 10, no. 6, Article ID e0129834, 2015. View at Publisher · View at Google Scholar · View at Scopus
  132. L. W. S. Finley, A. Carracedo, J. Lee et al., “SIRT3 opposes reprogramming of cancer cell metabolism through HIF1α destabilization,” Cancer Cell, vol. 19, no. 3, pp. 416–428, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. S. He, C. He, H. Yuan, S. Xiong, Z. Xiao, and L. Chen, “The SIRT3 expression profile is associated with pathological and clinical outcomes in human breast cancer patients,” Cellular Physiology and Biochemistry, vol. 34, no. 6, pp. 2061–2069, 2014. View at Publisher · View at Google Scholar · View at Scopus
  134. F. Yu, Q. Xu, D. D. Wu, A. T. Lau, and Y. M. Xu, “The prognostic and clinicopathological roles of sirtuin-3 in various cancers,” PLoS one, vol. 11, no. 8, Article ID e0159801, 2016. View at Publisher · View at Google Scholar
  135. S. M. Jeong, C. Xiao, L. W. S. Finley et al., “SIRT4 has tumor-suppressive activity and regulates the cellular metabolic response to dna damage by inhibiting mitochondrial glutamine metabolism,” Cancer Cell, vol. 23, no. 4, pp. 450–463, 2013. View at Publisher · View at Google Scholar · View at Scopus
  136. C. Sebastián, B. M. M. Zwaans, D. M. Silberman et al., “The histone deacetylase SIRT6 Is a tumor suppressor that controls cancer metabolism,” Cell, vol. 151, no. 6, pp. 1185–1199, 2012. View at Publisher · View at Google Scholar · View at Scopus
  137. S. Zhang, P. Chen, Z. Huang et al., “Sirt7 promotes gastric cancer growth and inhibits apoptosis by epigenetically inhibiting miR-34a,” Scientific Reports, vol. 5, article 9787, 2015. View at Publisher · View at Google Scholar · View at Scopus
  138. Q. Geng, H. Peng, F. Chen, R. Luo, and R. Li, “High expression of Sirt7 served as a predictor of adverse outcome in breast cancer,” International Journal of Clinical and Experimental Pathology, vol. 8, no. 2, pp. 1938–1945, 2015. View at Google Scholar · View at Scopus
  139. H.-L. Wang, R.-Q. Lu, S.-H. Xie et al., “SIRT7 exhibits oncogenic potential in human ovarian cancer cells,” Asian Pacific Journal of Cancer Prevention, vol. 16, no. 8, pp. 3573–3577, 2015. View at Publisher · View at Google Scholar · View at Scopus
  140. R. J. Gaudana, M. R. Gokulgandhi, S. H. S. Boddu, and A. K. Mitra, “Recent overview of ocular patents,” Recent Patents on Drug Delivery and Formulation, vol. 6, no. 2, pp. 95–106, 2012. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Moniot, M. Weyand, and C. Steegborn, “Structures, substrates, and regulators of mammalian Sirtuins—opportunities and challenges for drug development,” Frontiers in Pharmacology, vol. 3, article no. 16, 2012. View at Publisher · View at Google Scholar · View at Scopus
  142. S. D. Süssmuth, S. Haider, G. B. Landwehrmeyer et al., “An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease,” British Journal of Clinical Pharmacology, vol. 79, no. 3, pp. 465–476, 2015. View at Publisher · View at Google Scholar · View at Scopus